Literature DB >> 25538205

Progress in aldosteronism: a review of the prevalence of primary aldosteronism in pre-hypertension and hypertension.

George Piaditis1, Athina Markou2, Labrini Papanastasiou2, Ioannis I Androulakis3, Gregory Kaltsas2.   

Abstract

Primary aldosteronism (PA) secondary to excessive and/or autonomous aldosterone secretion from the renin-angiotensin system accounts for ∼10% of cases of hypertension and is primarily caused by bilateral adrenal hyperplasia (BAH) or aldosterone-producing adenomas (APAs). Although the diagnosis has traditionally been supported by low serum potassium levels, normokalaemic and even normotensive forms of PA have been identified expanding further the clinical phenotype. Moreover, recent evidence has shown that serum aldosterone correlates with increased blood pressure (BP) in the general population and even moderately raised aldosterone levels are linked to increased cardiovascular morbidity and mortality. In addition, aldosterone antagonists are effective in BP control even in patients without evidence of dysregulated aldosterone secretion. These findings indicate a higher prevalence of aldosterone excess among hypertensive patients than previously considered that could be attributed to disease heterogeneity, aldosterone level fluctuations related to an ACTH effect or inadequate sensitivity of current diagnostic means to identify apparent aldosterone excess. In addition, functioning aberrant receptors expressed in the adrenal tissue have been found in a subset of PA cases that could also be related to its pathogenesis. Recently a number of specific genetic alterations, mainly involving ion homeostasis across the membrane of zona glomerulosa, have been detected in ∼50% of patients with APAs. Although specific genotype/phenotype correlations have not been clearly identified, differential expression of these genetic alterations could also account for the wide clinical phenotype, variations in disease prevalence and performance of diagnostic tests. In the present review, we critically analyse the current means used to diagnose PA along with the role that ACTH, aberrant receptor expression and genetic alterations may exert, and provide evidence for an increased prevalence of aldosterone dysregulation in patients with essential hypertension and pre-hypertension.
© 2015 European Society of Endocrinology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25538205     DOI: 10.1530/EJE-14-0537

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  36 in total

1.  Adrenalectomy for Primary Aldosteronism: Significant Variability in Work-Up Strategies and Low Guideline Adherence in Worldwide Daily Clinical Practice.

Authors:  Wessel M C M Vorselaars; Dirk-Jan van Beek; Diederik P D Suurd; Emily Postma; Wilko Spiering; Inne H M Borel Rinkes; Gerlof D Valk; Menno R Vriens
Journal:  World J Surg       Date:  2020-06       Impact factor: 3.352

2.  Adrenal Tissue-Specific Deletion of TASK Channels Causes Aldosterone-Driven Angiotensin II-Independent Hypertension.

Authors:  Nick A Guagliardo; Junlan Yao; Eric J Stipes; Sylvia Cechova; Thu H Le; Douglas A Bayliss; David T Breault; Paula Q Barrett
Journal:  Hypertension       Date:  2019-02       Impact factor: 10.190

3.  Structure of human cortisol-producing cytochrome P450 11B1 bound to the breast cancer drug fadrozole provides insights for drug design.

Authors:  Simone Brixius-Anderko; Emily E Scott
Journal:  J Biol Chem       Date:  2018-11-13       Impact factor: 5.157

Review 4.  Primary Aldosteronism: Cardiovascular Outcomes Pre- and Post-treatment.

Authors:  Gregory L Hundemer
Journal:  Curr Cardiol Rep       Date:  2019-07-27       Impact factor: 2.931

Review 5.  5th International ACC Symposium: The New Genetics of Benign Adrenocortical Neoplasia: Hyperplasias, Adenomas, and Their Implications for Progression into Cancer.

Authors:  Lawrence S Kirschner; Constantine A Stratakis
Journal:  Horm Cancer       Date:  2015-12-18       Impact factor: 3.869

6.  Assessment of the Aldosteronona resolution score as a predictive resolution score of hypertension after adrenalectomy for aldosteronoma in French patients.

Authors:  Ludwig Pasquier; Medhi Kirouani; Florian Fanget; Claire Nomine; Cécile Caillard; Vincent Arnault; Jean-Baptiste Finel; Niki Christou; Muriel Mathonnet; Christophe Trésallet; Antoine Hamy; Loïc de Calan; Laurent Brunaud; Fabrice Menegaux; Jean Christophe Lifante; Jean Benoit Hardouin; Delphine Drui; Éric Mirallié; Claire Blanchard
Journal:  Langenbecks Arch Surg       Date:  2017-01-22       Impact factor: 3.445

Review 7.  Primary Aldosteronism: a Continuum from Normotension to Hypertension.

Authors:  Taweesak Wannachalee; Adina F Turcu
Journal:  Curr Cardiol Rep       Date:  2021-07-01       Impact factor: 2.931

Review 8.  Mouse models of adrenocortical tumors.

Authors:  Kaitlin J Basham; Holly A Hung; Antonio M Lerario; Gary D Hammer
Journal:  Mol Cell Endocrinol       Date:  2015-12-08       Impact factor: 4.102

9.  Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study.

Authors:  Gregory L Hundemer; Gary C Curhan; Nicholas Yozamp; Molin Wang; Anand Vaidya
Journal:  Lancet Diabetes Endocrinol       Date:  2017-11-09       Impact factor: 32.069

10.  A clinical prediction score using age at diagnosis and saline infusion test parameters can predict aldosterone-producing adenoma from idiopathic adrenal hyperplasia.

Authors:  H T Leung; Y C Woo; C H Y Fong; K C B Tan; E Y F Lau; K W Chan; J Y Y Leung
Journal:  J Endocrinol Invest       Date:  2019-09-16       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.